Subclinical myocardial disease by cardiac magnetic resonance imaging and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons. by Chew, Kara W et al.
UCLA
UCLA Previously Published Works
Title
Subclinical myocardial disease by cardiac magnetic resonance imaging 
and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons.
Permalink
https://escholarship.org/uc/item/6sj3h70n
Journal
The Journal of international medical research, 45(6)
ISSN
0300-0605
Authors
Chew, Kara W
Liu, Chia-Ying
Ambale-Venkatesh, Bharath
et al.
Publication Date
2017-12-01
DOI
10.1177/0300060517708919
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Special Issue: Cardiac Magnetic Resonance Assessment
of the Heart
Subclinical myocardial
disease by cardiac magnetic
resonance imaging and
spectroscopy in healthy
HIV/Hepatitis C
virus-coinfected persons
Kara W. Chew1, Chia-Ying Liu2,3,
Bharath Ambale-Venkatesh3, Diana Liao1,
Tamara B. Horwich1, Joa˜o A.C. Lima3,
David A. Bluemke2,3, J. Paul Finn4,
Adeel A. Butt5,6,7 and Judith S. Currier1
Abstract
Objective: The contribution of hepatitis C virus (HCV) infection to the risk of heart failure in
human immunodeficiency virus (HIV)-coinfected persons is unknown. The objective was to
characterize cardiac function and morphology in HIV-treated coinfected persons.
Methods: In a cross-sectional study, HIV-infected patients virologically suppressed on antiretro-
viral therapy without known cardiovascular disease or diabetes mellitus underwent cardiac
magnetic resonance imaging and spectroscopy for measures of cardiac function, myocardial
fibrosis, and steatosis.
Results: The study included 18 male patients with a median age of 44 years. Of these, 10 had
untreated HCV coinfection and eight had HIV monoinfection. Global systolic and diastolic function
in the cohort were normal, and median myocardial fat content was 0.48% (interquartile range
0.35–1.54). Left ventricular (LV) mass index and LV mass/volume ratio were significantly greater in
the HIV/HCV-coinfected group compared with the HIV-monoinfected group. In the
HIV-monoinfected group, there was more myocardial fibrosis as measured by extracellular
volume fraction.
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Conclusions: There were differences between HIV/HCV-coinfected and HIV-monoinfected
patients in cardiac structure and morphology. Larger studies are needed to examine whether HIV
and HCV independently contribute to mechanisms of heart failure.
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Introduction
Human immunodeficiency virus (HIV)
infection is associated with an increased
risk for cardiovascular disease (CVD) com-
plications, including myocardial, pericar-
dial, and vascular disease.1 The observed
increased risk is mediated by various mech-
anisms, including HIV replication and the
associated immune activation and inflam-
mation, complications of antiretroviral ther-
apy (ART) including metabolic toxicities
such as dyslipidemia, insulin resistance and
lipodystrophy, and higher rates of substance
use and smoking.1 The association between
hepatitis C virus (HCV) infection and CVD
is less well established, but suggested by an
increasing number of studies to date.2–4
While most investigations in HIV and
HCV have focused on atherosclerotic dis-
ease and ischemic heart disease, a higher risk
of heart failure has been reported even in the
absence of pre-existing coronary artery dis-
ease.5,6 HIV and HCV infection, which
differ in terms of the interactions of their
viral life cycles with host lipid metabolism
and immune modulation, may distinctly
influence risk for CVD, including risk of
heart failure.
Accumulating but limited data in HIV-
infected persons, primarily by echocardiog-
raphy and only recently by cardiac magnetic
resonance imaging (MRI) and magnetic
resonance spectroscopy (MRS), suggests
significant left ventricular (LV) dysfunction,
left ventricular hypertrophy (LVH),
myocardial fibrosis, and myocardial stea-
tosis (intramyocardial triglyceride content)
in HIV-infected persons without known
CVD, all of which may be associated with
future risk of clinical heart failure.7–11 In
previous studies, confounding by HIV vir-
emia was inconsistently accounted for and
the impact of virologic suppression upon
these findings is unknown, given persistent
HIV viremia is associated with greater
immune activation and inflammation,
which are thought to be major drivers of
HIV-associated CVD.7,8 Even more limited
are the data examining the association
between HCV and cardiac abnormalities,
but the existing literature suggests an asso-
ciation between HCV and altered LV
morphology, perhaps mediated by HCV-
associated metabolic changes.12,13 Lastly,
there are no prior data on HIV/HCV
coinfection and cardiac morphology. As
treated and virologically suppressed HIV-
infected persons are already at increased risk
of CVD and current therapeutic options are
limited to traditional approaches to CVD
risk modification, if HCV coinfection inde-
pendently promotes alterations in cardiac
morphology and function, HCV itself would
be a potential therapeutic target to reduce
risk for CVD in HIV. HCV treatment today
with interferon-free regimens is highly effect-
ive and well tolerated, yet access to treat-
ment is often still limited due to cost, with
priority given to those with more advanced
liver disease.14 Reducing CVD risk may be
an argument for earlier treatment of HCV
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regardless of liver disease stage, particularly
in aging HIV-infected patients for whom
CVD mortality is increasing.15
The aims of this pilot study were to
characterize cardiac function, fibrosis, and
steatosis by cardiac MRI and MRS in a
virologically suppressed asymptomatic HIV
cohort without known CVD, and explore
differences between HIV/HCV-coinfected
and HIV-monoinfected patients, where
there may be distinct mechanisms for car-
diac dysfunction and morphologic changes.
Patients and methods
Study design and patient selection
Study participants at least 18 years of age
and without known CVD or diabetes melli-
tus were recruited for this cross-sectional
study through advertisement and direct
referrals from university-affiliated and local
community-based HIV clinics and service
providers, and enrolled at a single site, the
University of California, Los Angeles
Center for Clinical AIDS Research and
Education, Los Angeles, CA, USA between
May 2012 and May 2014. All patients had
chronic HIV-1 infection and were on stable
ART for at least 6 months with HIV viral
load< 200 copies/ml and CD4 cell count>
200 cells/mm3. All HCV-coinfected patients
were required to be naı¨ve to HCV treatment
and have HCV RNA> 10,000 IU/ml within
90 days prior to study entry. HCV-negative
patients were required to have documenta-
tion of negative HCV serology within 1 year
prior to study entry. Persons with chronic
non-HCV liver disease, including coinfec-
tion with hepatitis B, were excluded. All
participants were required to have glomeru-
lar filtration rate of 60mL/min calculated
by theModification of Diet in Renal Disease
equation within 45 days prior to entry.16
This study was reviewed and approved by
the University of California, Los Angeles
Institutional Review Board (IRB; protocol
IRB#11-003092), and written informed
consent was obtained from each study par-
ticipant. The study protocol conforms to the
ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by
the UCLA IRB.
Clinical assessments
Standardized case report forms were used to
collect demographic data, duration of HIV
infection, smoking, substance use (cocaine,
heroin, andmethamphetamines), and alcohol
use history, nadir CD4 cell count, co-morbid
conditions, and concomitant medications
including complete ART history. Resting
blood pressure (the mean of two measure-
ments), weight, height, and waist circumfer-
ence were measured at study entry.
Participants were required to be fasting for
at least 8 h for fasting blood lipid panel and
glucose measurements. Complete blood
counts (CBC) and chemistries including hem-
atocrit, creatinine, and hepatic transaminases
(LFTs), HIV viral load, and HCV viral load
were collected or abstracted, if available,
from the medical record (CBC, LFTs,
and HIV RNA within 180 days, HCV
RNA within 90 days, and creatinine within
45 days of study entry). Hepatic fibrosis was
estimated by the FIB-4 equation: [age (years)
x aspartate aminotransferase (U/l)]/[platelet
count (109/l) x [alanine aminotransferase
(ALT, U/l)]1/2.17 ART was categorized by
current ART (integrase inhibitor, protease
inhibitor [PI], or non-nucleoside reverse tran-
scriptase [NNRTI]-based and type of
nucleos(t)ide reverse transcriptase, tenofovir
plus emtricitabine or abacavir plus lamivu-
dine) and a history of exposure to PI and
NNRTI therapy.
Cardiac magnetic resonance imaging and
magnetic resonance spectroscopy
Magnetic resonance imaging and 1H MRS
testing was performed during a single visit
on a 3.0 Tesla (3.0 T) Siemens Trio
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(Siemens Medical Solutions, Erlangen,
Germany), using a phased array body coil.
For LV function evaluation, a stack of short
axis cine images as well as 2-, 3-, and
4-chamber views using steady state free
precession imaging were acquired. Global
heart function, including myocardial mass,
volume, cardiac output, and ejection frac-
tion (EF) were measured through contour-
ing of the left ventricle using QMass
(Medis, Leiden, The Netherlands). To
assess regional heart function, LV myocar-
dial MR tagged images were obtained with
three short-axis scan planes (10mm thick-
ness; gap of 5mm) around the midlevel of
the LVmyocardium. The taggedMR images
were analyzed using HARP (Diagnosoft,
Morrisville, NC, USA) to obtain measures
of circumferential strain and strain rate. The
strain relaxation index (SRI) was also
calculated from the strain and strain rate
curves as detailed previously.18 An ECG-
gated phase contrast gradient-echo sequence
with velocity encoding was performed to
measure blood flow across the mitral valve
for determination of LV diastolic function.
The resulting biphasic diastolic inflow pat-
tern consisted of two peaks, representing the
early filling phase and the atrial contraction.
Analysis of the early filling phase and the
atrial contraction were performed by calcu-
lating their peak filling rates and ratio of the
peak filling rates (E/A) using QFlow
(Medis). Modified Look-Locker inversion
recovery (MOLLI) sequence was used for
T1 mapping before and 10 and 25min after
injection of 0.2mmol/kg of gadopentetate
dimeglumine. Long-axis images were
acquired with TR/TE/flip angle¼ 3.9msec/
1.95msec/50, FOV¼ 360x360mm,
matrix¼ 240x192, and slice thick-
ness¼ 8mm. Late (15-min delay) gadolin-
ium enhancement (LGE) images were
acquired to assess for focal myocardial
scar, in the same planes as the cine images.
Extracellular volume (ECV) fraction, as the
primary measure of diffuse myocardial
fibrosis, was derived from the T1 values
within the septal myocardium, LV blood
pool and patients’ hematocrit, calculated as
the partition coefficient x (1-hematocrit).19
Using all pre- and post-contrast T1 times,
partition coefficient was calculated as the
slope of the (fitted) line of the pre- and post-
contrast myocardium R1 (1/T1) plotted
against the pre- and post-contrast R1 of
blood.20 Both ECV and LGE images were
analyzed using QMass (Medis). The
4-chamber cine images were used for the
measurement of epicardial and pericardial
adipose tissue area as described previ-
ously.21 The measurements were made in
the end-diastolic phase using a ClearCanvas
DICOM image viewer (Synaptive Medical,
Toronto, Canada).22 Epicardial fat was
characterized as the areas of high intensity
layer between the myocardium and the
visceral pericardium, and pericardial fat as
that outside the parietal pericardium. The
short-axis cine images acquired were also
used to guide in delineation of the areas.
Subcutaneous and visceral fat volumes were
measured from three transverse slices of the
body at the L4–L5 level by semi-automated
segmentation of axial images from a single-
shot spin echo sequence.
1H MRS protocol and analysis
Cine images of the left ventricle were used to
position the spectroscopic volume (6-ml
voxel) within the interventricular septum.
Patients were instructed to breathe normally
during spectroscopy. Two MRS spectra
were recorded with electrocardiogram
(ECG)-gated single voxel point-resolved
spectroscopy sequence, with navigator
across the liver-lung interface to reduce
breathing effects. One spectrum (32 aver-
ages) was recorded with WET water sup-
pression and another spectrum (eight
averages) was recorded without water sup-
pression. Outer volume suppression using
saturation bands was applied to exclude the
1696 Journal of International Medical Research 45(6)
lipids from ventricular blood flow and epi-
cardial triglycerides. The same imaging
sequence was also applied for 1H MRS of
the liver, utilizing an 8ml voxel positioned
within the liver, avoiding obvious vessels
and the edge of the liver. Magnetic reson-
ance user interface (MRUI) software
(Jana Starcˇukova´, Institute of Scientific
Instruments, Academy of Sciences of the
Czech Republic, Brno, Czech Republic) was
used to process data.23 The area under
signals from methylene and methyl groups
of fatty acids in triglycerides was quantified
using the Advanced Magnetic Resonance
fitting algorithm (Amares) and related
to water in unsuppressed spectra.24
Myocardial and hepatic triglyceride content
were directly expressed as a percentage of fat
to water signal ratios.
Statistical analyses. All patients with cardiac
MRI and MRS data were included in the
statistical analyses. Cardiac MRI and MRS
were read by two investigators (C-Y.L. and
B.A.) who were blinded to the HCV status
of the participants. The statistical analyses
were pre-specified in a data analysis plan.
Summary data are presented as median and
interquartile range (IQR) for continuous
variables and as proportions for categorical
variables. Given the small sample size, cat-
egorical variables were compared using
Fisher’s exact tests and continuous variables
using non-parametric (Wilcoxon) methods.
Bivariate regression models were used to
explore associations between baseline clin-
ical characteristics and radiographic or
spectroscopic measures, including the asso-
ciation between myocardial fat and diastolic
strain rate, liver fat, duration of HIV infec-
tion, visceral fat (corrected for body surface
area [BSA] by the DuBois formula),25 tri-
glycerides, glucose, smoking status (current
versus former and smoking pack-years),
duration of ART, and type of current
ART; ECV and diastolic strain rate, SRI,
peak circumferential systolic strain (Ecc),
and FIB-4; diastolic strain rate or Ecc and
cocaine use (ever versus never), current
CD4, duration of HIV infection, and type
of current ART; Ecc and end diastolic mass
(EDM) index (EDM/BSA) and EDM/end
diastolic volume (EDV); diastolic strain rate
and EDM index and EDM/EDV; SRI and
EDM index and EDM/EDV; and mitral
valve E/A ratio and ECV, EDM index, and
EDM/EDV ratio. As this was an explora-
tory study, sample size calculations were not
performed prospectively and adjustments
were not made for multiple comparisons.
All statistical analyses were performed using
the SAS statistical package, version 9.4
(SAS Institute Inc., Cary, NC, USA).
A two-sided P-value 0.05 was considered
statistically significant.
Results
Eighteen patients, all male, 10 with HIV/
HCV coinfection and eight with HIV only,
underwent cardiac MRI and MRS and were
included in the analysis. Two HIV/HCV-
coinfected patients did not have evaluable
MRS and were excluded from the MRS
analyses. Table 1 summarizes the baseline
characteristics andMRI andMRS indices of
the study cohort. Overall, a minority had
traditional risk factors for CVD such as
hypertension and dyslipidemia, but there
were high rates of current or prior smoking
and substance use, particularly alcohol and
prior stimulant use. Of six participants on
lipid-lowering therapy, three were on
3-hydroxy-3-methyl-glutaryl-Co-A reduc-
tase inhibitors, one was on niacin, and two
were on fish oil or flax seed daily. HIV/
HCV-coinfected and HIV-monoinfected
patients were similar in most demographic,
behavioral, and clinical characteristics rele-
vant to cardiovascular risk. While smoking
status examined by current or past smoking
history was similar between the two groups,
HIV/HCV-coinfected patients had a greater
number of reported smoking pack years,
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Table 1. Clinical and cardiac magnetic resonance imaging and 1H magnetic resonance spectroscopy
characteristics of the cohort overall (n¼ 18) and stratified by hepatitis C virus (HCV) status.
Characteristic
Overall cohort
n¼ 18
HIV/HCV-coinfected
group n¼ 10
HIV-monoinfected
group n¼ 8
Statistical
significancea
Age, years 44.0 (39.0, 48.0) 45.5 (41.0, 50.0) 43.0 (31.5, 47.0) NS
Race
White 6 (33) 3 (30) 3 (38) NS
Black 8 (44) 5 (50) 3 (38)
Other 4 (22) 2 (20) 2 (25)
Body mass index, kg/m2 26.3 (23.9, 29.1) 28.6 (25.7, 29.4) 24.1 (22.0, 26.3) P¼ 0.03
Waist circumference, cm 89.2 (88.0, 98.7) 98.0 (89.0, 101.3) 88.8 (87.0, 89.0) NS
Hypertension 4 (22) 2 (20) 2 (25) NS
Systolic blood
pressure, mmHG
116.3 (112.5, 124.0) 115.3 (113.0, 119.0) 116.8 (111.8, 127.5) NS
Diastolic blood
pressure, mmHG
71.0 (67.0, 78.0) 71.5 (71.0, 76.0) 68.0 (64.0, 85.5) NS
Dyslipidemia 7 (39) 3 (30) 4 (50) NS
On lipid-lowering
therapy
6 (33) 2 (20) 4 (50) NS
Alcohol status
Current 11 (61) 5 (50) 6 (75) NS
Former 5 (28) 4 (40) 1 (13)
Never 2 (11) 1 (10) 1 (13)
Smoking status
Current 8 (44) 5 (50) 3 (38) NS
Former 7 (39) 4 (40) 3 (38)
Never 3 (17) 1 (10) 2 (25)
Smoking pack years
(n¼ 15, current or
former smokers only)
4.60 (1.43, 12.50) 10.00 (3.25, 13.50) 3.00 (1.43, 9.00) NS
Cocaine use
Current 0 (0) 0 (0) 0 (0) NS
Former 10 (56) 6 (40) 4 (50)
Never 8 (44) 4 (40) 4 (50)
Years since HIV diagnosis 11.4 (5.9, 17.9) 8.9 (4.8, 19.4) 13.9 (7.4, 17.4) NS
Years on ART 6.80 (2.10, 15.10) 6.25 (2.10, 15.20) 7.40 (4.90, 16.25) NS
Current ART
Ritonavir-boosted PI 6 (33) 4 (40) 2 (25) NS
NNRTI 6 (33) 2 (20) 4 (50)
Integrase inhibitor 5 (28) 3 (30) 2 (25)
IntegraseþNNRTI 1 (6) 1 (10) 0 (0)
CD4 nadir (n¼ 9 for
HIV/HCV-coinfected
group, n¼ 7 for
HIV-monoinfected
group), cells/mm3
303 (116, 420) 373 (300, 500) 172 (25, 350) P¼ 0.05
Current CD4 cell count,
cells/mm3
753 (550, 887) 768 (679, 909) 557 (436, 887) NS
ALT, U/l 39.0 (19.0, 88.0) 79.5 (43.0, 97.0) 22.0 (14.5, 34.5) P¼ 0.03
Total cholesterol, mg/dl 158.5 (136.0, 186.0) 155.5 (136.0 174.0) 158.5 (138.5, 188.5) NS
LDL-C, mg/dl 92.8 (69.5, 114.2) 87.4 (61.8, 114.2) 92.8 (78.9, 118.3) NS
HDL-C, mg/dl 41.4 (36.6, 46.3) 38.7 (32.3, 46.3) 44.0 (36.8, 46.7) NS
Triglycerides, mg/dl 96.0 (73.0, 119.0) 107.0 (88.0, 147.0) 79.5 (71.5, 109.0) NS
(continued)
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although this did not reach statistical sig-
nificance. Notably, body mass index (BMI)
was significantly higher in the HIV/HCV-
coinfected group compared with HIV-
monoinfected group (P¼ 0.03), falling in
the overweight range and suggesting poten-
tially greater metabolic disease despite simi-
lar cholesterol and fasting glucose levels.
With regard to HIV disease, the overall
group appeared quite healthy with current
CD4 cell counts> 500 cells/mm3, but the
HIV/HCV-coinfected group had evidence of
having initiated ART earlier in HIV disease
with a higher CD4 nadir. The distribution of
current ART class (ritonavir-boosted PI,
NNRTI, and integrase) was similar between
the two groups and only one subject (in the
HIV/HCV-coinfected group) was on an
abacavir backbone. All but one participant
had HIV RNA< 48 copies/ml at baseline.
With regard to liver disease, as expected,
ALT was significantly higher in the HIV/
HCV-coinfected group compared with the
HIV-monoinfected group (P¼ 0.03); a
single subject in the HIV/HCV-coinfected
group had a diagnosis of cirrhosis, and the
median FIB-4 score was low, suggesting
overall low rates of hepatic fibrosis in the
Table 1. Continued.
Characteristic
Overall cohort
n¼ 18
HIV/HCV-coinfected
group n¼ 10
HIV-monoinfected
group n¼ 8
Statistical
significancea
Fasting glucose, mg/dl 88.0 (85.0, 95.0) 88.5 (84.0, 95.0) 88.0 (86.0, 96.5) NS
FIB-4 score 0.93 (0.63, 1.38) 1.05 (0.83, 1.36) 0.76 (0.60, 2.13) NS
Myocardial fat
(n¼ 8 for HIV/HCV-
coinfected group), %
0.48 (0.35, 1.54) 0.45 (0.35, 1.19) 0.51 (0.33, 1.62) NS
Liver fat (n¼ 8 for
HIV/HCV group), %
1.93 (1.33, 4.28) 2.30 (1.38, 4.04) 1.75 (1.06, 4.76) NS
EDM index, g/m2 56.81 (48.22, 61.45) 60.75 (55.53, 63.51) 48.93 (45.56, 55.38) P¼ 0.05
EDM/EDV, g/ml 0.72 (0.63, 0.75) 0.75 (0.72, 0.77) 0.60 (0.57, 0.69) P< 0.01
ESV index, ml/m2 33.70 (28.29, 40.74) 33.70 (28.29, 39.76) 33.63 (28.47, 45.12) NS
EDV index, ml/m2) 80.95 (74.54, 85.47) 78.97 (74.54, 84.88) 82.94 (75.30, 94.24) NS
Mitral valve E/A 1.25 (1.01, 1.43) 1.23 (0.94, 1.43) 1.29 (1.08, 1.80) NS
Diastolic strain rate 0.11 (0.09, 0.14) 0.11 (0.10, 0.14) 0.10 (0.06, 0.13) NS
Strain relaxation index 1.43 (1.07, 2.18) 1.17 (1.07, 1.67) 2.09 (1.21, 2.95) NS
Peak circumferential
systolic strain, Ecc
–18.43 (–19.92, –15.60) –17.70 (–19.92, –15.60) –18.51 (–20.64, –16.90) NS
Ejection fraction, % 57.93 (52.00, 63.16) 58.67 (52.00, 59.87) 57.86 (52.13, 63.79) NS
Extracellular
volume fraction
0.27 (0.25, 0.31) 0.25 (0.24, 0.26) 0.31 (0.29, 0.32) P< 0.01
Epicardial fat, mm2 1012.0 (837.0, 1201.0) 937.5 (837.0, 1201.0) 1048.0 (860.0, 1180.0) NS
Pericardial fat, mm2 719.5 (366.0, 1352.0) 822.5 (560.0, 1412.0) 504.0 (167.0, 994.5) NS
Subcutaneous
fat/BSA, ml/m2
105.66 (68.23, 122.96) 114.11 (68.23, 123.56) 87.38 (70.17, 109.72) NS
Visceral fat/BSA, ml/m2 70.27 (53.19, 86.16) 71.99 (66.45, 86.16) 59.51 (49.47, 100.45) NS
Data presented as median (interquartile range) or n of patients (%).
aCategorical variables were compared using Fisher’s exact tests and continuous variables using non-parametric (Wilcoxon)
methods.
HIV, human immunodeficiency virus; ART, antiretroviral therapy; PI, protease inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; ALT, alanine aminotransferase; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol; FIB-4 score calculated using: [age (years) x aspartate aminotransferase (U/l)]/[platelet count (109/l)
x [ALT (U/l)]1/2; EDM, end-diastolic mass; EDM index, EDM/BSA; EDV, end-diastolic volume; ESV, end-systolic volume; ESV
index, ESV/BSA; EDV, end-diastolic volume; EDV index, EDV/BSA; E/A, ratio of the peak filling rates; BSA, body surface area;
NS, no significant between-group difference (P> 0.05).
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study cohort. Hematologic indices (CBC
and international normalized ratio) were
normal (data not shown); and renal function
was preserved in the cohort, although
nonsignificantly lower in the HIV/HCV-
coinfected group (median 86.5 versus
95.3ml/min in the HIV-monoinfected
group).
Overall median myocardial fat (%) was
0.48 (IQR 0.35–1.54) and similar between
HIV-monoinfected and HIV/HCV-coin-
fected groups. Participants without a history
of HIV PI exposure (n¼ 5) had three times
the degree of myocardial fat of those with a
history of PI use (n¼ 12), but this was not
statistically significant (median [IQR]¼
1.35% [0.35–1.90] versus 0.46% [0.26–
0.64], respectively). Cardiac function meas-
ures suggested similar or worse diastolic
function in the HIV/HCV-coinfected group
compared with the HIV-monoinfected
group and normal systolic function in both
groups (Table 1). In unadjusted analyses,
four (22%) patients had an abnormal mitral
valve E/A ratio (<1), three of 10 (30%) in
the HIV/HCV-coinfected group and one of
eight (13%) in the HIV-monoinfected
group, but the difference between the
groups was not significant. Two patients in
the HIV-monoinfected group had evidence
of a focal myocardial scar, one at the
inferior right ventricular insertion and the
other in the basal anterolateral wall, sug-
gesting prior ischemic disease.
There were notable morphologic findings
in the cohort. Overall, ECV values were at
the upper limit of normal and there was
significantly greater myocardial fibrosis by
ECV in the HIV-monoinfected group versus
the HIV/HCV-coinfected group (median
ECV 0.31 versus 0.25, respectively,
P< 0.01; meanSD ECV 0.30 0.02
versus 0.26 0.03, respectively). Five of the
18 participants had an abnormal ECV>
0.30; four in the HIV-monoinfected group
and one in the HIV/HCV-coinfected group.
In contrast, there was significantly greater
LV mass and EDM/EDV ratio in the HIV/
HCV-coinfected group versus the HIV-
monoinfected group (P¼ 0.05 and
P< 0.01, respectively; Table 1).
Subcutaneous and visceral fat volumes
were greater in the HIV/HCV-coinfected
versus the HIV-monoinfected group, but
not significantly (Table 1).
There were significant associations of
myocardial fibrosis and LV mass, but not
myocardial steatosis, with select diastolic
and systolic function measures, and signifi-
cant associations between myocardial fat
and other metabolic and fat deposition
measures. Specifically, by bivariate regres-
sion including all patients, myocardial fat
was not associated with diastolic strain rate
or SRI. Degree of liver fat was associated
with the degree of myocardial fat (P¼ 0.013,
b¼ 0.099) and level of fasting glucose was a
strong predictor of myocardial fat content
(P< 0.001, b¼ 0.095) (Table 2). Visceral fat
(indexed for BSA) approached statistical
significance in its association with myocar-
dial fat (P¼ 0.059, b¼ 0.013) and was sig-
nificantly associated with epicardial fat
(P< 0.01, b¼ 4.99), but not serum triglycer-
ide level. Duration of HIV infection and
ART and baseline ART type were not
associated with the degree of myocardial
fat. ECV was not associated with diastolic
strain rate, nor with Ecc, but was associated
with SRI (P¼ 0.017, b¼ 0.157). LV mass
and EDM/EDV ratio were associated with
systolic strain (Ecc) (P¼ 0.036, b¼ 0.163
and P< 0.01, b¼ 18.69, respectively), but
not with diastolic strain measures, although
near statistical significance for E/A ratio
(P¼ 0.07, b¼ –2.18). Hepatic fibrosis by
FIB-4 score was not associated with myo-
cardial fibrosis (ECV). Additional bivariate
analyses exploring substance use and HIV
parameters as predictors of diastolic and
systolic strain measures were not revealing,
including absence of associations with his-
tory of cocaine use, duration of HIV infec-
tion, baseline CD4 cell count, andART type.
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Discussion
This pilot study of HIV-monoinfected and
HIV/HCV-coinfected persons found signals
of differences in cardiac structure and
morphology by HCV status on comprehen-
sive cardiac MRI imaging, with greater
myocardial fibrosis in HIV-monoinfected
persons and greater LV mass in HIV/
HCV-coinfected persons. These morpho-
logic differences suggest that HIV and
untreated HCV infection, and their inter-
action, may alter the myocardium distinctly.
Hypothesized mechanisms for these mor-
phologic differences may include differences
in viral infection-driven inflammation and
metabolic dysfunction, such as insulin resist-
ance, hepatic steatosis, lipid derangements,
lipodystrophy and cardiac lipotoxicity. Both
HIV and HCV are associated with increased
risk for insulin resistance; in HIV, insulin
resistance is associated with ART and
lipodystrophy; and in HCV, where the
association is well established but the mech-
anisms less well understood, it may relate to
direct interference by HCV in insulin
signaling.26,27 Insulin resistance and hyper-
insulinemia may independently promote
myocardial cell proliferation and LV hyper-
trophy.28 In this current study, the HIV/
HCV-coinfected patients had more signs of
metabolic abnormalities than the HIV-
monoinfected patients, with higher BMI,
waist circumference, triglyceride levels, and
hepatic steatosis, although absent hyperten-
sion, suggesting that greater metabolic dis-
ease and insulin resistance from HCV
coinfection could be driving the LV mass
differences seen. Others have found greater
LV mass in HCV-monoinfected patients
similar to HCV-negative hypertensive
patients, correlating with HOMA-IR.12 To
our knowledge, no studies have directly
compared HIV/HCV-coinfected and
HIV-monoinfected patients with regard to
cardiac function or insulin resistance, and
teasing out the relative contributions of each
virus and their interaction may provide
insight into expected cardiac complications
and best management.
In this current cohort, diffuse myocardial
fibrosis was greater in HIV-monoinfected
Table 2. Bivariate linear regression for associations with cardiac steatosis and function in the overall cohort
of study participants (n¼ 18).
Outcome Predictor
Parameter
estimate
Statistical
significance
Myocardial fat, % Age, years 0.056 P¼ 0.012
Hepatic fat, % 0.099 P¼ 0.013
Fasting glucose, mg/dl 0.095 P< 0.001
Visceral fat/BSA 0.013 NS
Serum triglyceride level, mg/dl –0.0007 NS
Duration of ART, years 0.042 NS
Strain relaxation index, ms Age, years 0.021 NS
ECV, % 0.157 P¼ 0.017
EDM/BSA 0.033 NS
EDM/EDV –0.575 NS
Peak circumferential
systolic strain, Ecc
Age, years 0.111 NS
EDM/BSA 0.163 P¼ 0.036
EDM/EDV 18.69 P< 0.01
BSA, body surface area; ART, antiretroviral therapy; ECV, extracellular volume fraction; EDM, end diastolic mass; EDV, end
diastolic volume; NS, no significant association (P> 0.05).
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patients compared with HIV/HCV-coin-
fected patients, with a difference of 6% of
the myocardium being affected. Amongst
the HIV-monoinfected participants, half
had ECV> 30%, which is generally con-
sidered to be abnormal.29 Several studies
have demonstrated the correlation of
increasing ECV values across a range similar
to those in this current study with impaired
diastolic function and LV stiffness.30,31 In
one study, the difference in median ECV
between participants with heart failure with
preserved EF and without heart failure, and
between those with systolic failure and
without heart failure, was smaller than
seen in this current study.30 In another
study of obese adults, the hazard ratio for
hospitalization for heart failure was 1.92
(95% confidence interval [CI] 1.40, 2.65) for
every 5% increase in ECV, and 2.50 (95%
CI 1.59, 3.95) for death.32 In that study, the
risk of hospitalization for heart failure or
death was increased in participants with
ECV> 25% compared with those with
ECV< 25%.32 Thus, the 6% difference in
ECV between HIV-monoinfected and HIV/
HCV-coinfected patients in the present
study is likely to be clinically significant;
and in addition, three-quarters of all par-
ticipants in the present study had ECV>
25%. Why ECV was greater amongst
HIV-monoinfected compared with HIV/
HCV-coinfected patients is unclear. One
notable difference between the HIV-mono-
infected and HIV/HCV-coinfected groups
was a lower CD4 nadir in the monoinfected
group, which may be associated with greater
immune activation, inflammation, and
fibrogenesis. However, in a larger cohort of
HIV-monoinfected patients previously
reported,11 no association was seen between
ECV and nadir CD4 or soluble biomarkers
of inflammation and immune activation.
Longer duration of untreated HIV infection
in the HIV-monoinfected group leading to a
greater chronic inflammatory state driving
myocardial collagen deposition is also a
consideration as a potential mechanism for
greater ECV. The HIV-monoinfected group
had a longer duration of time since HIV
diagnosis (median of 13.9 versus 8.9 years,
respectively) despite relatively similar dur-
ation on ART. Considering other associ-
ations with ECV, in a previous study,
systolic blood pressure was associated with
ECV but blood pressure was higher than in
this current cohort, where systolic blood
pressure was similar between coinfected and
monoinfected participants and normal.11 It
could also be considered that differences in
past or present ART and associated cardi-
otoxicity may have contributed to differ-
ences in myocardial fibrosis, but the limited
size of this present study and of others to
date preclude such examination. Larger
studies will be needed to confirm if there is
a difference in myocardial fibrosis between
coinfected and monoinfected patients and to
elucidate the etiology of myocardial fibrosis
in HIV-infected patients without
hypertension.
In the current study, ECV values in the
HIV-monoinfected group were greater than,
and in the HIV/HCV-coinfected group simi-
lar to, that observed in HIV-uninfected
controls in a previous study that examined
a US cohort with similar demographic and
clinical characteristics to the cohort in the
current study, with MR also conducted on a
3.0 T MR scanner.11 In the current study,
ECV values in the HIV-infected group were
greater than those in the HIV-infected
group in the previous study (meanSD
0.30 0.02 versus 0.28 0.04, respectively),
where ECV values were statistically signifi-
cantly greater than uninfected controls
(ECV mean SD 0.26 0.03).11 In one
European study that used a 1.5 T MR
scanner, T1 mapping short MOLLI values
were also significantly greater in HIV-
infected compared with uninfected controls
(ECV not reported);7 while another smaller
European study that used a 3.0 T MR
scanner found no difference in ECV between
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HIV-infected and uninfected persons.33
Mean ECV values in HIV-uninfected con-
trols in previous studies11,33 and in a non-
HIV study of healthy subjects compared
with patients with different cardiac disease
conditions29 were similar. Thus, ECV values
in uninfected healthy subjects without base-
line CVD appear consistently in the 0.25–
0.26 range and the higher ECV values in the
HIV-infected patients in the current study
may reflect a true increase from healthy
myocardium due to either HIV infection or
other CVD risk factors more prevalent in
HIV. Further studies with carefully selected
controls are needed to tease out the contri-
bution of HIV itself to myocardial fibrosis.
While systolic and diastolic function were
similar in HIV/HCV-coinfected and HIV-
monoinfected patients in the current study,
and overall were normal in this apparently
healthy and relatively young, diverse cohort
with well-controlled HIV and without overt
metabolic disease, the alterations in myo-
cardial fibrosis and myocardial mass with
suggest the potential for future cardiac
dysfunction and major cardiovascular
events in HIV and HIV/HCV infected
persons.
Overall, there was significant myocardial
steatosis in the current cohort, similar to
that seen in a previously reported HIV
cohort,7 where myocardial fat content was
greater in HIV-infected persons compared
with uninfected controls, but lower than that
seen in another published study.11 Similarly,
less liver fat was seen in the present cohort
than in this latter previously published
study; in contrast, the degree of diffuse
myocardial fibrosis by ECV was similar.11
Some of these differences may potentially be
explained by differences in the participants
enrolled in the two cohorts.11 For example,
the cohort in the present study were younger
by 5 years and healthier with less metabolic
derangement, and none was women com-
pared with the previous study, in which age,
fasting glucose, triglyceride level, and female
sex were associated with myocardial fat.11
Compared with the previous cohort, none of
the participants in the current study had
diabetes mellitus or were female, and they
had a lower BMI, fasting glucose, and
triglyceride levels.11 The current study par-
ticipants also differed in HIV status: all had
a suppressed HIV viral load compared with
84.2% of the previously reported cohort;
although it should be noted that the viral
load cut-off for a suppressed viral load
differed between the two studies (50 copies/
ml in the previous study versus 200 copies/
ml in the current study).11 The patients in
the current study also had a higher reported
nadir CD4 cell count compared with the
previously reported cohort (303 versus 236
cells/ml, respectively).11 Interestingly and in
direct contrast to pre-study expectations,
while not statistically significant, partici-
pants in the current study without a history
of HIV PI use had three times greater
myocardial steatosis content compared
with participants with a history of PI use.
Given the small sample size (five in the no PI
group), this difference may have occurred by
chance and not reflect a true difference
related to ART exposure, but is striking
and should be explored in larger studies.
Other studies have either not assessed asso-
ciations between specific ART type and
myocardial steatosis or reported no associ-
ation between specific ART subclasses and
myocardial fat content, without providing
specific values for each subgroup.7,11
Understanding if specific ART exposure is
associated with increased myocardial fat
content may improve assessment of individ-
ual risk for cardiac dysfunction as well as
understanding of mechanisms of intramyo-
cardial lipid accumulation in HIV-infected
patients. Myocardial steatosis has been
implicated in the pathogenesis of LV hyper-
trophy, diastolic dysfunction, nonischemic
cardiomyopathy, and overt heart fail-
ure.34–37 The correlation between hepatic
steatosis and myocardial steatosis, yet lack
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of correlation between hepatic fibrosis
and myocardial fibrosis, suggests poten-
tially differing pathogenic mechanisms of
end-organ fibrosis and the contribution of
steatosis to fibrosis development in these
organs.
Strengths of the current study include:
(i) prospective enrollment of participants
utilizing strict pre-specified eligibility cri-
teria, thus limiting heterogeneity of the
cohort; (ii) limited confounding by active
HIV viremia as all participants were
required to have documented HIV virologic
suppression, which has been a limitation of
previous studies of cardiac imaging in HIV-
infected persons;7,11 and (iii) utilization of
standardized MRI and 1H MRS protocols
with blinding of MRI and MRS readers to
the HCV status of participants, reducing
bias or technical deviations. Significant limi-
tations of the study include: (i) its small
sample size, which limited the ability to
explore associations between HIV and
HCV-specific factors and the outcomes of
interest and conduct adjusted analyses, such
as to address potential differences between
HIV and HIV/HCV groups in demograph-
ics, traditional cardiovascular risk factors,
and HIV disease severity; (ii) inclusion of
patients from a single site, limiting general-
izability of the study; (iii) lack of matching
of HIV and HIV/HCV patients, although
they were similar in many key characteris-
tics; and (iv) absence of an HIV-uninfected
control group. Such a control group would
allow assessment of the independent contri-
bution of HIV and HCV to the risk of or
unique mechanisms for cardiac abnormal-
ities, particularly given that the cardiac MR
measures are influenced by differences in
technique such as field strength and pulse
sequences used and region of measurement,
and direct comparisons with other studies
of HIV-uninfected persons may not be
appropriate.38
In conclusion, despite the small sample
size, this current study found evidence of
expected relationships between cardiac
abnormalities detected by MRI/MRS and
systolic and diastolic function, including
associations between myocardial fibrosis
and diastolic dysfunction and LV mass and
systolic dysfunction. The current study
found similar associations as with larger
studies utilizing cardiac MRI/MRS in HIV-
infected cohorts, with differences in findings
between this and other cohorts highlighting
that the prevalence and degree of subclinical
cardiac abnormalities, even in healthier HIV
cohorts, will likely vary significantly depend-
ing on patient selection. Understanding the
observed findings will require better charac-
terization of the overlap between HIV,
metabolic disease, and other co-morbidities
such as viral hepatitis. Larger studies are
needed to further explore these preliminary
findings and to examine the effect of HIV
and HCV on cardiac function with
adjustment for potentially confounding
demographic, behavioral, and clinical char-
acteristics, as well as to assess the impact of
HCV treatment on measures of cardiac
function. Understanding differences in the
pathogenesis of cardiac disease in HIV and
HCV-infected persons will allow for
improved clinical risk assessment for heart
failure, arrhythmia, and sudden death, as
well as identify pathways, such as cardiac
fibrogenesis and hemodynamic alterations
related to liver disease, and systolic versus
diastolic dysfunction, which may be differ-
entially targeted for the treatment or pre-
vention of cardiac complications in HIV
and HCV. There is a very high prevalence of
HCV infection and coinfection globally.39–41
Such affected patients are aging and
at increasing risk for extra-hepatic and
non-AIDS complications, with cardiovas-
cular disease being a leading cause. The
contribution of HCV infection to cardio-
vascular disease, and specifically the under-
explored conditions of myocardial disease
and heart failure, deserves further
investigation.
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